New Data on Subcutaneous Bortezomib

被引：1
|
作者：
Moreau, Philippe [1 ]
Touzeau, Cyrille [1 ]
机构：
[1] Univ Hosp, Dept Hematol, F-44093 Nantes, France
来源：
ACTA HAEMATOLOGICA | 2015年 / 133卷 / 01期
关键词：
RELAPSED MULTIPLE-MYELOMA; INTRAVENOUS BORTEZOMIB; COMBINATION REGIMENS; INJECTION;
D O I：
10.1159/000362639
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：26 / 28
页数：3
相关论文
共 50 条
  • [41] REVERSIBLE POSTERIOR LEUKOENCEPHALOPATHY SYNDROME SECONDARY TO SUBCUTANEOUS BORTEZOMIB: A LESS FREQUENT ADVERSE REACTION
    Gonzalez Angela, Blanco
    Elguezabal Jasone, Uriarte
    Garcia Lara, Palacios
    Martinez Irene, Leal
    Juan Ignacio, Rodriguez Gutierrez
    Fernandez Olga, Arce
    Agustin Nagore, Viteri
    Ma Mar, Sarmiento de la Iglesia
    de Lucas Fernando, Marco
    HAEMATOLOGICA, 2016, 101 : 312 - 312
  • [42] Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients:a Meta-analysis
    牟时代
    艾利莎
    秦铀
    胡豫
    CurrentMedicalScience, 2018, 38 (01) : 43 - 50
  • [43] Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma
    Tomohiko Kamimura
    Toshihiro Miyamoto
    Shuichiro Takashima
    Noriko Yokota
    Yong Chong
    Yoshikiyo Ito
    Koichi Akashi
    International Journal of Hematology, 2012, 96 : 525 - 527
  • [44] A SINGLE CENTRE CLINICAL EXPERIENCE OF THE EFFICACY AN SAFETY PROFILE OF SUBCUTANEOUS VERSUS INTRAVENOUS BORTEZOMIB
    Randall, K.
    Qureshi, I.
    Bokhari, S.
    HAEMATOLOGICA, 2014, 99 : 636 - 637
  • [45] Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma
    Mateos, Maria-Victoria
    San Miguel, Jesus F.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (02) : 117 - 124
  • [46] Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients: a Meta-analysis
    Shi-dai Mu
    Li-sha Ai
    You Qin
    Yu Hu
    Current Medical Science, 2018, 38 : 43 - 50
  • [47] SUBCUTANEOUS VERSUS INTRAVENOUS BORTEZOMIB: A REAL-LIFE STUDY ON MULTIPLE MYELOMA PATIENTS
    Mangiacavalli, S.
    Cocito, F.
    Ferretti, V.
    Cartia, C.
    Cazzola, M.
    Corso, A.
    HAEMATOLOGICA, 2015, 100 : 519 - 519
  • [48] Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma
    Kamimura, Tomohiko
    Miyamoto, Toshihiro
    Takashima, Shuichiro
    Yokota, Noriko
    Chong, Yong
    Ito, Yoshikiyo
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (04) : 525 - 527
  • [49] Efficacy of Subcutaneous Bortezomib in the Management of Patients with Multiple Myeloma or Relapsed Mantle Cell Lymphoma
    Podar, Klaus
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2014, 6 : 15 - 23
  • [50] SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION OF BORTEZOMIB IN PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE IN A SINGLE INSTITUTION
    Lopez San Roman, I.
    De Miguel, D.
    Golbano, N.
    Diaz Morfa, M.
    Morales, D.
    Arbeteta, J.
    Herrero, S.
    Subira, D.
    Pinedo, B.
    HAEMATOLOGICA, 2012, 97 : 603 - 603
12345